白血病スクリーニングの世界市場

白血病スクリーニングの世界市場は2030年までに105億米ドルに達する見込み

2024年に76億米ドルと推定される白血病スクリーニングの世界市場は、2024年から2030年にかけてCAGR 5.6%で成長し、2030年には105億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである完全血球計数検査は、CAGR 5.9%を記録し、分析期間終了時には27億米ドルに達すると予測されます。骨髄吸引・生検検査セグメントの成長率は、分析期間中CAGR 4.2％と推定されます。

米国市場は21億米ドル、中国はCAGR8.9%で成長予測

米国の白血病スクリーニング市場は2024年に21億米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 8.9％を辿り、2030年までに21億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.7%と5.5%と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界の白血病スクリーニング市場- 主要動向と促進要因のまとめ

なぜ早期スクリーニングが白血病管理の中心になりつつあるのか？

白血球に影響を及ぼす血液悪性腫瘍の一群である白血病は、特にその急速な発症と多彩な症状により、世界的に大きな健康負担を課し続けています。早期かつ正確なスクリーニングは、予後を改善し、タイムリーな治療介入を可能にし、治療戦略を調整する上で不可欠です。生存率は診断時の病期と強く関連しているため、世界中のヘルスケアシステムは、より広範ながん早期発見プログラムの一環として、白血病スクリーニングを優先しています。スクリーニングは、遺伝的素因を持つ人、放射線や化学療法を受けたことのある人、骨髄異形成症候群のような特定の白血病予備軍を含む高リスク集団にとって特に重要です。

技術の進歩は、白血病の検出法を再構築しています。従来の全血球算定（CBC）と末梢塗抹検査は、最小残存病変（MRD）と早期突然変異の検出を可能にする洗練された分子診断とフローサイトメトリー技術によって増強されつつあります。これらのツールは、特に急性骨髄性白血病（AML）、慢性リンパ性白血病（CLL）、急性リンパ芽球性白血病（ALL）のような白血病の亜型の区別において、臨床的意思決定を強化しています。プレシジョン・メディシンが腫瘍学のスタンダードになるにつれて、白血病スクリーニングは単純な検出だけでなく、疾患のモニタリングやリスク層別化を含むようになりつつあります。

高精度とアクセシビリティを可能にする診断技術はどのように進化しているのか？

分子診断学、リキッドバイオプシー、ゲノミクスにおける革新は、白血病スクリーニングの精度を著しく高めています。次世代シーケンサー（NGS）は、FLT3、NPM1、BCR-ABLなどの白血病関連遺伝子の変異を同定するために現在広く使用されており、サブタイプの分類や標的治療の選択を可能にしています。マルチプレックスPCRアッセイやデジタル液滴PCRも、従来の方法では同定が困難な融合遺伝子や低頻度の変異を検出するために採用されています。これらの技術は、臨床医が白血病をその初期段階（しばしば症状が現れる前）に発見し、治療反応を高感度でモニターすることを可能にしています。

これと並行して、POC（ポイント・オブ・ケア）検査ツールも開発され、スクリーニングの分散化とアクセスの改善が図られています。マイクロ流体デバイス、ラボオンチップ技術、AI主導の解釈を用いたモバイル診断プラットフォームは、集団スクリーニングプログラムを支援するために試験中です。これらのツールは、電子カルテ（EHR）の統合やクラウドベースのデータ解析と組み合わされ、白血病検出のワークフローを合理化し、集団レベルのサーベイランスの広範な実施を可能にしています。

どのような動向が臨床導入と公衆衛生戦略に影響を与えているか？

臨床および公衆衛生戦略は、リスクベースおよび年齢をターゲットとすることをますます重視するようになっています。小児白血病、特にALLは、統合的スクリーニングと早期介入により生存率が著しく改善したが、成人白血病は、非特異的な症状やルーチンの血液学的検査がないため、診断上の課題となっています。数カ国の国家がん対策プログラムでは、特に環境や職業上の危険因子が高い場合、血液悪性腫瘍スクリーニングをより広範なNCD予防の枠組みに組み込んでいます。

高度診断の保険適用と腫瘍学インフラへの投資の拡大も市場の成長を形成しています。政府や非営利団体は、早期検査を促進するために、診断能力の向上、遺伝カウンセリングプログラム、啓発キャンペーンなどに投資しています。さらに、血液学と腫瘍学の共同研究がバイオマーカーの発見を後押しし、新規スクリーニング法の臨床応用を加速させています。このような動向は診断の遅れを減少させ、個別化白血病治療への移行を支援しています。

世界の白血病スクリーニング市場の成長を牽引しているのは？

白血病スクリーニング市場の成長は、分子診断学の進歩、白血病罹患率の増加、精密医療の枠組みの拡大など、いくつかの要因によってもたらされます。特に高齢化した集団や遺伝的素因のある人々の間で、早期発見ツールに対する需要が高まっており、スクリーニングの取り組みが広まっています。フローサイトメトリーやNGSのような高感度検査が利用可能になったことで、早期診断、リスクプロファイリング、疾患モニタリングが可能になり、リキッドバイオプシーは非侵襲的でスケーラブルな繰り返し評価の選択肢として台頭してきています。

普遍的ながん検診に向けた政策転換、ヘルスケア支出の増加、国民の意識向上により、先進国・新興経済諸国ともに市場開拓が進んでいます。さらに、AIとデジタルヘルスツールの統合により、診断スループットが加速し、集団全体でのスクリーニングプログラムの実施が可能になっています。日常的な腫瘍治療の一環として分子プロファイリングや遺伝子スクリーニングを推奨するよう臨床ガイドラインが進化するにつれて、世界の白血病スクリーニング市場は、技術革新と、より早期かつ正確ながん発見の緊急ニーズの両方によって、持続的な拡大の態勢を整えています。

セグメント

検査タイプ（全血球算定、骨髄吸引・生検、フローサイトメトリー、細胞遺伝学的分析、ポリメラーゼ連鎖反応、免疫表現型分類、その他の検査タイプ）、疾患タイプ（急性リンパ性白血病、急性骨髄性白血病、慢性リンパ性白血病、慢性骨髄性白血病、その他の疾患タイプ）、年齢層（小児、成人、老年）、最終用途（病院・クリニック、診断研究所、調査機関、その他の最終用途）

調査対象企業の例（全37件）

• Abbott Laboratories
• Adaptive Biotechnologies
• Alercell
• ArcherDX
• Asuragen（Bio-Techne）
• Beckman Coulter
• Bio-Rad Laboratories
• Danaher Corporation
• DiaSorin
• Exact Sciences
• F. Hoffmann-La Roche Ltd
• Grail
• Guardant Health
• Illumina
• Invivoscribe
• Natera
• Prenetics
• QIAGEN
• Quest Diagnostics
• SkylineDx

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Leukemia Screening Market to Reach US$10.5 Billion by 2030

The global market for Leukemia Screening estimated at US$7.6 Billion in the year 2024, is expected to reach US$10.5 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Complete Blood Count Test, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Bone Marrow Aspiration & Biopsy Test segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.1 Billion While China is Forecast to Grow at 8.9% CAGR

The Leukemia Screening market in the U.S. is estimated at US$2.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 8.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Leukemia Screening Market - Key Trends & Drivers Summarized

Why Is Early Screening Becoming Central to Leukemia Management?

Leukemia, a group of hematologic malignancies affecting white blood cells, continues to impose a significant global health burden, especially due to its rapid onset and variable presentation. Early and accurate screening is vital in improving prognosis, enabling timely therapeutic interventions, and tailoring treatment strategies. With survival rates strongly linked to stage at diagnosis, healthcare systems worldwide are prioritizing leukemia screening as part of broader oncology early-detection programs. Screening is particularly critical for high-risk populations, including individuals with genetic predispositions, prior exposure to radiation or chemotherapy, and those with certain pre-leukemic conditions like myelodysplastic syndromes.

Technological advancements are reshaping leukemia detection methods. Traditional complete blood count (CBC) and peripheral smear tests are being augmented by sophisticated molecular diagnostics and flow cytometry techniques, which enable the detection of minimal residual disease (MRD) and early-stage mutations. These tools are enhancing clinical decision-making, especially in distinguishing between leukemia subtypes such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL). As precision medicine becomes a standard in oncology, leukemia screening is moving beyond simple detection to encompass disease monitoring and risk stratification.

How Are Diagnostic Technologies Evolving to Enable Precision and Accessibility?

Innovations in molecular diagnostics, liquid biopsy, and genomics are significantly enhancing the precision of leukemia screening. Next-generation sequencing (NGS) is now widely used to identify mutations in leukemia-associated genes such as FLT3, NPM1, and BCR-ABL, allowing for subtype classification and targeted therapy selection. Multiplex PCR assays and digital droplet PCR are also being employed to detect fusion genes and low-frequency mutations that are otherwise difficult to identify through conventional methods. These technologies are enabling clinicians to catch leukemia in its earliest stages-often before symptoms manifest-and monitor treatment response with high sensitivity.

In parallel, point-of-care (POC) testing tools are being developed to decentralize screening and improve access, particularly in low-resource settings where laboratory infrastructure may be limited. Mobile diagnostic platforms using microfluidic devices, lab-on-a-chip technologies, and AI-driven interpretation are being tested to support mass screening programs. These tools, combined with electronic health record (EHR) integration and cloud-based data analytics, are streamlining leukemia detection workflows and enabling broader implementation of population-level surveillance.

What Trends Are Influencing Clinical Adoption and Public Health Strategy?

Clinical and public health strategies are increasingly emphasizing risk-based and age-targeted leukemia screening. Pediatric leukemia, particularly ALL, has seen significant survival improvements due to integrated screening and early intervention, but adult leukemia remains a diagnostic challenge due to nonspecific symptoms and the absence of routine hematologic checks. National cancer control programs in several countries are incorporating hematologic malignancy screening into broader NCD prevention frameworks, especially where environmental or occupational risk factors are high.

Insurance coverage for advanced diagnostics and growing investment in oncology infrastructure are also shaping market growth. Governments and nonprofit organizations are investing in diagnostic capacity building, genetic counseling programs, and awareness campaigns to promote early testing. Additionally, hematology-oncology research collaborations are fueling biomarker discovery and accelerating the clinical translation of novel screening modalities. These trends are helping to reduce diagnostic delays and support the move toward personalized leukemia care.

What Is Driving Growth in the Global Leukemia Screening Market?

The growth in the leukemia screening market is driven by several factors, including advances in molecular diagnostics, increasing leukemia incidence, and expanding precision medicine frameworks. Rising demand for early detection tools, particularly among aging populations and genetically predisposed individuals, is supporting widespread screening initiatives. The availability of highly sensitive tests such as flow cytometry and NGS is enabling earlier diagnosis, risk profiling, and disease monitoring, while liquid biopsy is emerging as a non-invasive and scalable option for repeat assessments.

Policy shifts toward universal cancer screening, rising healthcare expenditures, and improved public awareness are expanding market access across both developed and emerging economies. Furthermore, the integration of AI and digital health tools is accelerating diagnostic throughput and enabling population-wide implementation of screening programs. As clinical guidelines evolve to recommend molecular profiling and genetic screening as part of routine oncology care, the global leukemia screening market is poised for sustained expansion, driven by both technological innovation and the urgent need for earlier, more precise cancer detection.

SCOPE OF STUDY:

The report analyzes the Leukemia Screening market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping, Other Test Types); Disease Type (Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types); Age Group (Pediatric, Adult, Geriatric); End-Use (Hospitals & Clinics, Diagnostic Laboratories, Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• Abbott Laboratories
• Adaptive Biotechnologies
• Alercell
• ArcherDX
• Asuragen (Bio-Techne)
• Beckman Coulter
• Bio-Rad Laboratories
• Danaher Corporation
• DiaSorin
• Exact Sciences
• F. Hoffmann-La Roche Ltd
• Grail
• Guardant Health
• Illumina
• Invivoscribe
• Natera
• Prenetics
• QIAGEN
• Quest Diagnostics
• SkylineDx

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Leukemia Screening - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Hematologic Cancers Drives Demand for Early and Accurate Leukemia Screening Solutions
  • Expansion of Genomic and Molecular Testing Capabilities Spurs Growth in Personalized Leukemia Risk Profiling
  • Government-Led Cancer Prevention Programs Strengthen Public Access to Routine Hematologic Screenings
  • Shift Toward Minimally Invasive Liquid Biopsy Techniques Supports Adoption in Early-Stage Leukemia Detection
  • Integration of AI and Machine Learning in Diagnostic Pathology Enhances Accuracy of Leukemia Risk Stratification
  • Growing Awareness Among Primary Care Providers Fuels Referrals for Preventive Leukemia Screening Tests
  • Surge in Pediatric and Geriatric Leukemia Cases Expands Target Population for Tailored Screening Protocols
  • Development of Cost-Effective, Point-of-Care Testing Kits Increases Accessibility in Low-Resource and Rural Settings
  • Inclusion of Leukemia Risk in Comprehensive Cancer Panels Drives Adoption of Multiplexed Screening Platforms
  • Rise in At-Home Testing and Direct-to-Consumer Health Trends Supports Demand for Remote Leukemia Screening Services
  • Expansion of Clinical Guidelines for High-Risk Populations Throws Spotlight on Family History-Based Screening Programs
  • Advancements in Flow Cytometry and Next-Gen Sequencing Enable High-Resolution Leukemia Detection Workflows
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Leukemia Screening Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Leukemia Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Leukemia Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Leukemia Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Complete Blood Count by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Complete Blood Count by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Complete Blood Count by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Bone Marrow Aspiration & Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Bone Marrow Aspiration & Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Bone Marrow Aspiration & Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Flow Cytometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Flow Cytometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Flow Cytometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Cytogenetic Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Cytogenetic Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Cytogenetic Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Polymerase Chain Reaction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Polymerase Chain Reaction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Immunophenotyping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Immunophenotyping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Immunophenotyping by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Chronic Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Chronic Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Chronic Lymphocytic Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Chronic Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Chronic Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Chronic Myeloid Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Acute Lymphoblastic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Acute Lymphoblastic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Acute Lymphoblastic Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Acute Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Acute Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Acute Myeloid Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Pediatric by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Geriatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Geriatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Geriatric by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 59: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 60: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Leukemia Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 62: USA Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: USA 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 68: USA Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: USA Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: USA 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 71: USA Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: USA Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: USA 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Canada 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 80: Canada Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Canada Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Canada 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 83: Canada Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Canada Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Canada 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Leukemia Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Japan 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Japan 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Japan 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 95: Japan Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Japan Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Japan 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Leukemia Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 98: China Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: China 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 101: China Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: China 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 104: China Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: China Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: China 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 107: China Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: China Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: China 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Leukemia Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Leukemia Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Leukemia Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Leukemia Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Europe 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Europe Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Europe 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 122: Europe Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Europe Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Europe 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Leukemia Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 125: France Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: France 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 128: France Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: France 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 131: France Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: France Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: France 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 134: France Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: France Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: France 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Leukemia Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Germany 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Germany Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Germany 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 143: Germany Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Germany Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Germany 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 146: Germany Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Germany Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Germany 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Italy 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Italy Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Italy 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 155: Italy Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Italy Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Italy 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 158: Italy Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Italy Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Italy 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Leukemia Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 161: UK Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: UK 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 164: UK Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: UK Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: UK 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 167: UK Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: UK Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: UK 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 170: UK Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: UK Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: UK 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Spain 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Spain Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Spain 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 179: Spain Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Spain Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Spain 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 182: Spain Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Spain Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Spain 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Russia 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Russia Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Russia 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 191: Russia Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Russia Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Russia 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 194: Russia Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Russia Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Russia 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Europe 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Europe Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Europe 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Europe Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Europe Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Europe 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Leukemia Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Leukemia Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Leukemia Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Asia-Pacific 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Asia-Pacific Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Asia-Pacific 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 221: Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Asia-Pacific Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Asia-Pacific 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Leukemia Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Australia 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Australia Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Australia 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 230: Australia Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Australia Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Australia 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 233: Australia Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Australia Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Australia 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Leukemia Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 236: India Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: India 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 239: India Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: India Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: India 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 242: India Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: India Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: India 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 245: India Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: India Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: India 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: South Korea 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: South Korea Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: South Korea 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 254: South Korea Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: South Korea Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: South Korea 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 257: South Korea Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: South Korea Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: South Korea 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Rest of Asia-Pacific Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Rest of Asia-Pacific 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 269: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Rest of Asia-Pacific Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Rest of Asia-Pacific 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Leukemia Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Leukemia Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Leukemia Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Leukemia Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Latin America 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Latin America Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Latin America 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 281: Latin America Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Latin America Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Latin America 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 284: Latin America Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Latin America Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Latin America 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Argentina 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Argentina Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Argentina 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 293: Argentina Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Argentina Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Argentina 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 296: Argentina Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Argentina Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Argentina 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Brazil 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Brazil Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Brazil 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 305: Brazil Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Brazil Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Brazil 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 308: Brazil Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Brazil Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Brazil 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Mexico 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Mexico Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Mexico 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 317: Mexico Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Mexico Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Mexico 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 320: Mexico Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Mexico Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Mexico 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Rest of Latin America 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Rest of Latin America Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Rest of Latin America 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 332: Rest of Latin America Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Rest of Latin America Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Rest of Latin America 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Leukemia Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Leukemia Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Leukemia Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Leukemia Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Middle East 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Middle East Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Middle East 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 344: Middle East Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Middle East Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Middle East 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 347: Middle East Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Middle East Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Middle East 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Iran 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Iran Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Iran 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 356: Iran Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Iran Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Iran 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 359: Iran Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Iran Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Iran 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Israel 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Israel Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Israel 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 368: Israel Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Israel Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Israel 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 371: Israel Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Israel Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Israel 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Saudi Arabia 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Saudi Arabia Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Saudi Arabia 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 383: Saudi Arabia Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Saudi Arabia Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Saudi Arabia 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: UAE 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: UAE Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: UAE 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 392: UAE Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: UAE Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: UAE 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 395: UAE Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: UAE Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: UAE 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Rest of Middle East 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Rest of Middle East Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Rest of Middle East 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 407: Rest of Middle East Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Rest of Middle East Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Rest of Middle East 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Leukemia Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Leukemia Screening by Test Type - Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 412: Africa 15-Year Perspective for Leukemia Screening by Test Type - Percentage Breakdown of Value Sales for Complete Blood Count, Bone Marrow Aspiration & Biopsy, Flow Cytometry, Cytogenetic Analysis, Polymerase Chain Reaction, Immunophenotyping and Other Test Types for the Years 2015, 2025 & 2030
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Africa Historic Review for Leukemia Screening by Disease Type - Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 415: Africa 15-Year Perspective for Leukemia Screening by Disease Type - Percentage Breakdown of Value Sales for Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Disease Types, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia for the Years 2015, 2025 & 2030
  • TABLE 416: Africa Recent Past, Current & Future Analysis for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Africa Historic Review for Leukemia Screening by Age Group - Pediatric, Adult and Geriatric Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 418: Africa 15-Year Perspective for Leukemia Screening by Age Group - Percentage Breakdown of Value Sales for Pediatric, Adult and Geriatric for the Years 2015, 2025 & 2030
  • TABLE 419: Africa Recent Past, Current & Future Analysis for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 420: Africa Historic Review for Leukemia Screening by End-Use - Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 421: Africa 15-Year Perspective for Leukemia Screening by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION